Patents Examined by Agnieszka Boesen
  • Patent number: 11001844
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 11, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • Patent number: 10982189
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: April 20, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Bitao Liang, Wei Liu
  • Patent number: 10973906
    Abstract: Compositions are disclosed that induce broadly HIV theraputic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide sequences that are likely candidates for drugs which will offer effective treatment in such areas as Alzheimer's disease, psoriasis, multiple sclerosis and other diseases associated with the human inflammatory cascade as well as related retroviruses such as HTLV-1, the cause of tropical spastic paraparesis.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: April 13, 2021
    Assignee: Creative Bio-Peptides Inc.
    Inventor: Michael Ruff
  • Patent number: 10962539
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 30, 2021
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
  • Patent number: 10946078
    Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of canine atopic dermatitis (CAD). Furthermore, the invention provides methods for preventing or treating CAD. The compositions of the invention induce efficient immune responses, in particular antibody responses, in dogs and are, therefore, useful for the treatment and/or prevention of CAD.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: March 16, 2021
    Assignee: BENCHMARK ANIMAL HEALTH LTD.
    Inventor: Kaspars Tars
  • Patent number: 10947300
    Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 16, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
  • Patent number: 10948494
    Abstract: Methods and compositions are provided for the analysis of rare cells or other biological entities in a population, by contacting the population with a labeling nanoparticle comprising a VLP conjugated to a light emitting moiety and a specific binding moiety, then detecting the presence of bound nanoparticle by light emission.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 16, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: James Robert Swartz, Christopher C. Vanlang
  • Patent number: 10927151
    Abstract: The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 23, 2021
    Assignee: SANOFI PASTEUR INC.
    Inventors: Tod Dwayne Strugnell, Guadalupe Cortes-Garcia, Tim Alefantis
  • Patent number: 10927158
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: February 23, 2021
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo Chaparro
  • Patent number: 10920289
    Abstract: Methods and techniques to increase the reliability of detecting virus infections, particularly lymphotropism, to eliminate false negative reactions in testing blood for the presence of lymphotropic viruses during enzyme immunoassay (EIA) and polymerase chain reaction (PCR) testing, and to better detect viruses with lymphotropism in biological materials having a concentration of virus particles lower than the sensitivity threshold of existing EIA and PCR methods, thereby making the techniques of the present invention more reliable.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: February 16, 2021
    Inventor: Ovik Leonardovich Mkrtchyan
  • Patent number: 10912832
    Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: February 9, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Patrick C. H. Hsieh, Pei-Jung Wu, Steve Roffler, Bill Cheng
  • Patent number: 10900024
    Abstract: The present invention relates to a method for purifying viruses or virus-like particles using a crosslinked cellulose hydrate membrane and to a kit for purifying viruses or virus-like particles and the use thereof.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: January 26, 2021
    Assignee: Sartorius Stedim Biotech GmbH
    Inventors: Rebecca Petersen, Kathrin Schröder-Tittmann, Louis Villain
  • Patent number: 10898567
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 26, 2021
    Assignee: ISA PHARMACEUTICALS B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander Krebber, Johan Herman Kessler, Cornelis Joseph Maria Melief, Kitty Michelle Corinne Kwappenberg
  • Patent number: 10888615
    Abstract: Provided herein is a human monoclonal antibody 8D6 against hepatitis C virus (HCV) infection. The antibody binds to the E2 subunit of HCV capsid protein, and can prevent HCV from infecting susceptible host cells. By using the antibody variable region gene or the complementary determining region (CDR) gene, different forms of genetic engineering antibodies have been transformed and produced in any expression system of the prokaryotic and eukaryotic cells as therapeutics to prevent or treat HCV infection.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: January 12, 2021
    Assignee: SUZHOU GALAXY BIOPHARMA, CO., LTD.
    Inventors: Honglin Zhou, Jie Liu, Xin Dong, Bing Sun, Jiangjun Wang, Zhiyang Ling, Chunyan Yi, Chao Bian
  • Patent number: 10869920
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: December 22, 2020
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Government of the United States, as represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Patent number: 10864210
    Abstract: The present invention provides a composition and a combined medication method for treating an enterovirus infection. In particular, the present invention provides a composition for inhibiting enteroviruses, wherein the composition at least contains an inhibitor of a 3D virus protein and an inhibitor of a capsid protein, or a combination of an inhibitor of a 3C protein and an inhibitor of a 3A protein.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: December 15, 2020
    Assignee: INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES
    Inventors: Gang Zou, Ralf Altmeyer, Yizhuo Wang
  • Patent number: 10849945
    Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 1, 2020
    Assignee: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Brian Robert Champion, Alice Claire Noel Brown
  • Patent number: 10851160
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: December 1, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Chu Strasbourg, les Hopitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • Patent number: 10851350
    Abstract: Methods for producing viruses from adherent cells are provided. The methods include releasing virus from adherent host cells grown in a bioreactor, and purifying released virus by ultrafiltration and/or diafiltration. The methods can be used to manufacture viruses, including for clinical use, at reduced cost relative to conventional virus manufacturing methods.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: December 1, 2020
    Assignee: Genelux Corporation
    Inventors: Joseph Cappello, Richard J. Aguilar
  • Patent number: 10835552
    Abstract: Disclosed are a method for preparing a linseed polysaccharide having antiviral activity and immunological activity, food and healthare products and methods of treatment using the linseed polysaccharide. The method comprises the steps of: using the linseeds as raw materials, pulverizing the linseeds, separating the husks from the kernels of the linseeds, extracting by the microwave-assisted hot water extraction, deproteinizing by the Sevage method, carrying out ethanol precipitation, and freeze-drying to obtain the linseed crude polysaccharides, then carrying out ion-exchange column chromatography, Sephadex gel column chromatography, and ultra-filtration so as to obtain the linseed triple-helix polysaccharides.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 17, 2020
    Assignee: Jinan University
    Inventors: Yong Wang, Martin J. T. Reaney, Xiaofeng Li, Wenzhen Liao, Shan Liang, Yinglai Teng, Youn Young Shim, Peta-Gaye Gillian Burnett